Promising new shot for bulging eyes moves to final testing

NCT ID NCT07262476

Recruiting now Disease control Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called MHB018A for people with moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and discomfort. About 258 adults who completed earlier studies will receive injections every 4 weeks. The main goal is to see if the drug reduces eye bulging by at least 2 millimeters after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MHB018A injection
What this could lead to: If successful, this could provide a new treatment option to reduce eye bulging and control symptoms in people with thyroid eye disease.
What could go wrong: This is an open-label extension study, so results may be less reliable than blinded trials. The treatment may not work for everyone and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE, TED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE, TED

Contacts and locations

Locations

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 201419, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.